

# Sean D Sullivan Bscpharm

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8642375/sean-d-sullivan-bscpharm-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

104  
papers

4,279  
citations

30  
h-index

64  
g-index

109  
ext. papers

4,806  
ext. citations

3.7  
avg, IF

5.24  
L-index

#	Paper	IF	Citations
104	The potential long-term comparative effectiveness of larotrectinib versus entrectinib for treatment of metastatic TRK fusion colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 40-40	2.2	0
103	The potential long-term comparative effectiveness of larotrectinib versus regorafenib or trifluridine/tipiracil for treatment of metastatic TRK fusion colorectal cancer.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 41-41	2.2	
102	Systematic literature review (SLR) and network meta-analysis (NMA) of first-line therapies (1L) for locally advanced/metastatic urothelial carcinoma (la/mUC).. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 570-570	2.2	0
101	The potential long-term comparative effectiveness of larotrectinib vs standard of care for treatment of metastatic TRK fusion thyroid cancer, colorectal cancer, and soft tissue sarcoma.. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2022</b> , 1-9	1.9	
100	Successes and challenges of implementing a cancer care delivery intervention in community oncology practices: lessons learned from SWOG S1415CD.. <i>BMC Health Services Research</i> , <b>2022</b> , 22, 432	2.9	0
99	International reference pricing of pharmaceuticals in the United States: Implications for potentially curative treatments.. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2022</b> , 28, 566-572	1.9	
98	Clinical outcomes in high-hypoglycaemia-risk patients with type 2 diabetes switching to insulin glargine 300U/mL versus a first-generation basal insulin analogue in the United States : Results from the DELIVER High Risk real-world study. <i>Endocrinology, Diabetes and Metabolism</i> , <b>2021</b> , e00306	2.7	1
97	Are Drugs Priced in Accordance With Value? A Comparison of Value-Based and Net Prices Using Institute for Clinical and Economic Review Reports. <i>Value in Health</i> , <b>2021</b> , 24, 789-794	3.3	1
96	Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: A review of the DELIVER programme. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1713-1721	6.7	1
95	Cost-effectiveness of opicapone and entacapone in reducing OFF-time in Parkinson's disease patients treated with levodopa/carbidopa. <i>Journal of Medical Economics</i> , <b>2021</b> , 24, 563-569	2.4	3
94	Health care resource utilization and costs associated with nonadherence and nonpersistence to antidepressants in major depressive disorder. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2021</b> , 27, 223-239	1.9	4
93	Pharmacoeconomic Evaluations: Guidelines for Drug Purchasers. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2020</b> , 26, 689-695	1.9	1
92	Integrating Formal Technology Assessment into an Integrated Healthcare Delivery System: Smart Innovation. <i>International Journal of Technology Assessment in Health Care</i> , <b>2020</b> , 36, 58-63	1.8	4
91	The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2020</b> , 26, 981-986	1.9	6
90	Evolution of the AMCP Format for Formulary Submissions. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , <b>2020</b> , 26, 696-700	1.9	
89	Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus. <i>Current Medical Research and Opinion</i> , <b>2020</b> , 36, 571-581	2.5	6
88	Application of Health Technology Assessment (HTA) to Evaluate New Laboratory Tests in a Health System: A Case Study of Bladder Cancer Testing. <i>Academic Pathology</i> , <b>2020</b> , 7, 2374289520968225	1.3	1

87	A pragmatic randomized clinical trial of insulin glargine 300 U/mL vs first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 6-month outcomes of the ACHIEVE Control study. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 2004-2012	6.7	6
86	Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy. <i>Value in Health</i> , <b>2019</b> , 22, 661-668	3.3	33
85	Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real-world study. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 2123-2132	6.7	19
84	Effective stakeholder engagement: design and implementation of a clinical trial (SWOG S1415CD) to improve cancer care. <i>BMC Medical Research Methodology</i> , <b>2019</b> , 19, 119	4.7	14
83	The Economic Burden of Chronic Obstructive Pulmonary Disease in the Asia-Pacific Region: A Systematic Review. <i>Value in Health Regional Issues</i> , <b>2019</b> , 18, 121-131	1.6	8
82	Estimating Long-Term Survival for Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Chimeric Antigen Receptor Therapy: A Comparison of Standard and Mixture Cure Models. <i>Medical Decision Making</i> , <b>2019</b> , 39, 294-298	2.5	12
81	Treatment Patterns, Overall Survival, and Total Healthcare Costs of Advanced Merkel Cell Carcinoma in the USA. <i>Applied Health Economics and Health Policy</i> , <b>2019</b> , 17, 733-740	3.4	5
80	133-LB: High Hypoglycemia Risk Patients with T2D on First-Generation Basal Insulins (BI) in the U.S. Have a Lower Risk of Hypoglycemia after One Year following Switch to Insulin Glargine 300 U/mL (Gla-300) vs. First-Generation BIs (DELIVER - High Risk). <i>Diabetes</i> , <b>2019</b> , 68, 133-LB	0.9	3
79	Returns to scientific publications for pharmaceutical products in the United States. <i>Health Economics (United Kingdom)</i> , <b>2018</b> , 27, 282-293	2.4	0
78	Price elasticities of pharmaceuticals in a value based-formulary setting. <i>Health Economics (United Kingdom)</i> , <b>2018</b> , 27, 1788-1804	2.4	7
77	Association Between the Publication of Clinical Evidence and the Use of Bariatric Surgery. <i>Obesity Surgery</i> , <b>2018</b> , 28, 1321-1328	3.7	5
76	Pharmacists as health care providers: Lessons from California and Washington. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , <b>2018</b> , 1, 39-44	1.4	3
75	Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 2148-2158	6.7	48
74	Toward a Hedonic Value Framework in Health Care. <i>Value in Health</i> , <b>2017</b> , 20, 261-265	3.3	4
73	A stakeholder-informed randomized, controlled comparative effectiveness study of an order prescribing intervention to improve colony stimulating factor use for cancer patients receiving myelosuppressive chemotherapy: the TrACER study. <i>Journal of Comparative Effectiveness Research</i> , <b>2017</b> , 6, 461-470	2.1	7
72	Advanced Imaging and Receipt of Guideline Concordant Care in Women with Early Stage Breast Cancer. <i>International Journal of Breast Cancer</i> , <b>2016</b> , 2016, 2182985	2.3	4
71	Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report. <i>Value in Health</i> , <b>2015</b> , 18, 161-72	3.3	37 <sup>1</sup>
70	Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritis. <i>Value in Health</i> , <b>2015</b> , 18, 173-9	3.3	22

69	Association of early imaging for back pain with clinical outcomes in older adults. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 1143-53	27.4	73
68	Implementing Lung Cancer Screening Using Low-Dose Computed Tomography: Recommendations From an Expert Panel. <i>Journal of Oncology Practice</i> , <b>2015</b> , 11, e44-9	3.1	7
67	Role of Health Services Research in Producing High-Value Rehabilitation Care. <i>Physical Therapy</i> , <b>2015</b> , 95, 1703-11	3.3	10
66	Sedative Hypnotic Medication Use and the Risk of Motor Vehicle Crash. <i>American Journal of Public Health</i> , <b>2015</b> , 105, e64-9	5.1	43
65	A multifaceted hospitalist quality improvement intervention: Decreased frequency of common labs. <i>Journal of Hospital Medicine</i> , <b>2015</b> , 10, 390-5	2.7	52
64	Comparative effectiveness of imaging modalities to determine metastatic breast cancer treatment response. <i>Breast</i> , <b>2015</b> , 24, 3-11	3.6	11
63	An economic framework for preventive care advice. <i>Health Affairs</i> , <b>2014</b> , 33, 2034-40	7	8
62	Asthma Control and Cost in Latin America. <i>Value in Health Regional Issues</i> , <b>2014</b> , 5, 25-28	1.6	6
61	Cost-effectiveness models for chronic obstructive pulmonary disease: cross-model comparison of hypothetical treatment scenarios. <i>Value in Health</i> , <b>2014</b> , 17, 525-36	3.3	32
60	Comparing hospital-based resource utilization and costs for prostate cancer patients with and without bone metastases. <i>Applied Health Economics and Health Policy</i> , <b>2014</b> , 12, 547-57	3.4	14
59	Level of asthma control and health care utilization in Asia-Pacific countries. <i>Respiratory Medicine</i> , <b>2014</b> , 108, 271-7	4.6	30
58	Comparative effectiveness research in the United States: a progress report. <i>Journal of Medical Economics</i> , <b>2013</b> , 16, 295-7	2.4	3
57	Economic consequences of sequencing biologics in rheumatoid arthritis: a systematic review. <i>Journal of Medical Economics</i> , <b>2013</b> , 16, 391-6	2.4	24
56	Asthma outcomes: healthcare utilization and costs. <i>Journal of Allergy and Clinical Immunology</i> , <b>2012</b> , 129, S49-64	11.5	79
55	Prioritizing comparative effectiveness research for cancer diagnostics using a regional stakeholder approach. <i>Journal of Comparative Effectiveness Research</i> , <b>2012</b> , 1, 241-55	2.1	8
54	Cost-effectiveness of risk stratification for preventing type 2 diabetes using a multi-marker diabetes risk score. <i>Journal of Medical Economics</i> , <b>2011</b> , 14, 609-16	2.4	24
53	Evaluating HTA principles. <i>International Journal of Technology Assessment in Health Care</i> , <b>2010</b> , 26, 429-438	3.8	2
52	Are Key Principles for improved health technology assessment supported and used by health technology assessment organizations?. <i>International Journal of Technology Assessment in Health Care</i> , <b>2010</b> , 26, 71-8	1.8	42

51	A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus. <i>Pharmacotherapy</i> , <b>2009</b> , 29, 1280-8	5.8	10
50	Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone. <i>Cardiovascular Diabetology</i> , <b>2009</b> , 8, 12	8.7	16
49	Health technology assessment in health-care decisions in the United States. <i>Value in Health</i> , <b>2009</b> , 12 Suppl 2, S39-44	3.3	58
48	Key principles for the improved conduct of health technology assessments for resource allocation decisions. <i>International Journal of Technology Assessment in Health Care</i> , <b>2008</b> , 24, 244-58; discussion 362-8	1.8	264
47	A forensic evaluation of the National Emphysema Treatment Trial using the expected value of information approach. <i>Medical Care</i> , <b>2008</b> , 46, 542-8	3.1	10
46	The promise of specialty pharmaceuticals: are they worth the price?. <i>Journal of Managed Care Pharmacy</i> , <b>2008</b> , 14, S3-6		12
45	Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2007</b> , 22, 1494-9	4	18
44	Agreement between caregiver reported healthcare utilization and administrative data for children with asthma. <i>Journal of Asthma</i> , <b>2007</b> , 44, 189-94	1.9	12
43	Updated evaluation of the cost-effectiveness of lung volume reduction surgery. <i>Chest</i> , <b>2007</b> , 131, 823-832	3.3	41
42	Quality of clinical and economic evidence in dossier formulary submissions. <i>American Journal of Managed Care</i> , <b>2007</b> , 13, 401-7	2.1	7
41	Managing biotechnology in a network-model health plan: a U.S. private payer perspective. <i>Health Affairs</i> , <b>2006</b> , 25, 1347-52	7	5
40	Economic evaluation in the US: what is the missing link?. <i>Pharmacoeconomics</i> , <b>2006</b> , 24, 1163-8	4.4	23
39	Application of economic analyses in U.S. managed care formulary decisions: a private payer's experience. <i>Journal of Managed Care Pharmacy</i> , <b>2006</b> , 12, 726-35		26
38	Cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against venous thromboembolism in patients undergoing hip fracture surgery. <i>Value in Health</i> , <b>2006</b> , 9, 68-76	3.3	16
37	More Isn't Always Better: Cost-Effectiveness Analysis and the Case for Using a Split-Night Protocol. <i>Journal of Clinical Sleep Medicine</i> , <b>2006</b> , 02, 155-154	3.1	8
36	Development of a Quantifiable Symptom Assessment Tool for Patients with Chronic Bronchitis: The Chronic Bronchitis Symptoms Assessment Scale. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2005</b> , 2, 209-216	2	8
35	Practice-level effects of interventions to improve asthma care in primary care settings: the Pediatric Asthma Care Patient Outcomes Research Team. <i>Health Services Research</i> , <b>2005</b> , 40, 1737-57	3.4	35
34	Evidence, economics, and emphysema: Medicare's long journey with lung volume reduction surgery. <i>Health Affairs</i> , <b>2005</b> , 24, 55-66	0	30

33	A multisite randomized trial of the effects of physician education and organizational change in chronic asthma care: cost-effectiveness analysis of the Pediatric Asthma Care Patient Outcomes Research Team II (PAC-PORT II). <i>JAMA Pediatrics</i> , <b>2005</b> , 159, 428-34		50
32	The Burden of Obstructive Lung Disease Initiative (BOLD): Rationale and Design. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , <b>2005</b> , 2, 277-283	2	191
31	A multisite randomized trial of the effects of physician education and organizational change in chronic-asthma care: health outcomes of the Pediatric Asthma Care Patient Outcomes Research Team II Study. <i>JAMA Pediatrics</i> , <b>2004</b> , 158, 875-83		114
30	Rapporto costo-efficacia della terapia peginterferone $\alpha$ 2a + ribavirina in confronto a interferone $\alpha$ 2b + ribavirina in pazienti affetti da epatite cronica di tipo C precedentemente non trattati. <i>Pharmacoeconomics Italian Research Articles</i> , <b>2004</b> , 6, 105-114		3
29	Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C. <i>Pharmacoeconomics</i> , <b>2004</b> , 22, 257-65	4.4	55
28	A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery. <i>Pharmacoeconomics</i> , <b>2004</b> , 22, 605-20	4.4	24
27	Consensus guidelines for specialty pharmaceuticals: a best-practice approach for cost-effective management. <i>American Journal of Managed Care</i> , <b>2004</b> , 10, S242-4; discussion 245-51	2.1	2
26	The economics of venous thromboembolism prophylaxis: a primer for clinicians. <i>Chest</i> , <b>2003</b> , 124, 393S-396S		13
25	Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. <i>New England Journal of Medicine</i> , <b>2003</b> , 348, 2092-102	59.2	183
24	Emerging therapeutic strategies for asthma management. <i>Journal of Managed Care Pharmacy</i> , <b>2003</b> , 9, 14-21		4
23	Exploring new frontiers in asthma management for optimal therapeutic and economic outcomes. <i>Journal of Managed Care Pharmacy</i> , <b>2003</b> , 9, 2		3
22	Asthma in the United States: recent trends and current status. <i>Journal of Managed Care Pharmacy</i> , <b>2003</b> , 9, 3-7		26
21	A Randomized Controlled Clinical Trial to Improve Asthma Care for Children Through Provider Education and Health Systems Change: A Description of the Pediatric Asthma Care Patient Outcome Research Team (PAC-PORT II) Study Design. <i>Health Services and Outcomes Research Methodology</i> , <b>2003</b> , 4, 265-282	1.6	10
20	Resource costs for asthma-related care among pediatric patients in managed care. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2003</b> , 91, 251-7	3.2	40
19	Cost-effectiveness analysis of early intervention with budesonide in mild persistent asthma. <i>Journal of Allergy and Clinical Immunology</i> , <b>2003</b> , 112, 1229-36	11.5	61
18	Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery. <i>Pharmacoeconomics</i> , <b>2003</b> , 21, 477-96	4.4	48
17	Comparison of directly elicited preferences to preferences derived from the SF-36 in adults with asthma. <i>Medical Decision Making</i> , <b>2003</b> , 23, 323-34	2.5	25
16	The cost-effectiveness of an inner-city asthma intervention for children. <i>Journal of Allergy and Clinical Immunology</i> , <b>2002</b> , 110, 576-81	11.5	115

15	Health state preference assessment in diabetic peripheral neuropathy. <i>Pharmacoeconomics</i> , <b>2002</b> , 20, 1079-89	4.4	23
14	Health Economics <b>2002</b> , 657-671		2
13	Modeling the cost and outcomes of pharmacist-prescribed emergency contraception. <i>American Journal of Public Health</i> , <b>2001</b> , 91, 1443-5	5.1	30
12	Design issues for conducting cost-effectiveness analyses alongside clinical trials. <i>Annual Review of Public Health</i> , <b>2001</b> , 22, 129-41	20.6	38
11	The health economics of asthma and rhinitis. I. Assessing the economic impact. <i>Journal of Allergy and Clinical Immunology</i> , <b>2001</b> , 107, 3-8	11.5	439
10	AMCP Guidance for Submission of Clinical and Economic Evaluation Data to Support Formulary Listing in U.S. Health Plans and Pharmacy Benefits Management Organizations. <i>Journal of Managed Care Pharmacy</i> , <b>2001</b> , 7, 272-282		52
9	The economic burden of COPD. <i>Chest</i> , <b>2000</b> , 117, 5S-9S	5.3	394
8	Trends in the cost of illness for asthma in the United States, 1985-1994. <i>Journal of Allergy and Clinical Immunology</i> , <b>2000</b> , 106, 493-9	11.5	298
7	The economic burden of asthma in US children: estimates from the National Medical Expenditure Survey. <i>Journal of Allergy and Clinical Immunology</i> , <b>1999</b> , 104, 957-63	11.5	165
6	Intention-to-treat analysis in randomized trials: who gets counted?. <i>Journal of Clinical Pharmacology</i> , <b>1997</b> , 37, 667-72	2.9	16
5	National Asthma Education and Prevention Program working group report on the cost effectiveness of asthma care. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>1996</b> , 154, S84-95	10.2	117
4	A utility assessment of oral and intravenous ganciclovir for the maintenance treatment of AIDS-related cytomegalovirus retinitis. <i>Pharmacoeconomics</i> , <b>1996</b> , 10, 623-9	4.4	15
3	Home care reimbursement for intravenous ganciclovir therapy. <i>American Journal of Health-System Pharmacy</i> , <b>1996</b> , 53, 161-3	2.2	3
2	The economic costs of asthma: a review and conceptual model. <i>Pharmacoeconomics</i> , <b>1993</b> , 4, 14-30	4.4	51
1	The Burden of Obstructive Lung Disease Initiative (BOLD): Rationale and Design		3